Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma

ClinicalTrials.gov ID: NCT01124539

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01124539. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin) in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this study is to determine the 6-month Progression free survival (PFS) when intravenous (IV) AR-67 is administered in adults with confirmed recurrence of GBM who have not recently (\> 90 days) recurred after treatment bevacizumab (including patients who've received temazolamide, but no bevacizumab). The primary objective in the rapid bevacizumab failure group (\< 90 days) is to determine the 2-month PFS.

Study identification

NCT ID: NCT01124539
Recruitment status: Not listed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Arno Therapeutics; Industry
Enrollment: 58 participants

Conditions and interventions

Conditions

Interventions

AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin) Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 2009 (Type not available)
Primary completion: Sep 2014 (Actual)
Completion: Feb 2015 (Estimated)
Last update posted: Dec 9, 2014

2009 – 2015

United States locations

U.S. sites: 7
U.S. states: 6
U.S. cities: 7

Facility	City	State	ZIP	Site status
Northwestern University - Robert H Lurie Comprehensive Cancer Center	Chicago	Illinois	60611	—
University of Kentucky - Markey Cancer Center	Lexington	Kentucky	40536	—
North Shore - Long Island Jewish Hospital/Monter Cancer Center	Lake Success	New York	11042	—
Duke University Medical Center - The Preston Robert Tisch Brain Tumor Center	Durham	North Carolina	27710	—
Derrick L Davis Forsyth Regional Cancer Center	Winston-Salem	North Carolina	27103	—
The Ohio State University - James Comprehensive Cancer Center	Columbus	Ohio	43210	—
University of Utah - Huntsman Cancer Center	Salt Lake City	Utah	84112	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01124539, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Dec 9, 2014 · Synced Nov 15, 2026